Key Highlights

  • PAVM reported a preliminary Q3 net loss of US$13 million, versus US$6 million last year.
  • Fair-value changes on LUCD shares and the senior note produced a US$9.6 million non-cash charge.
  • LUCD began receiving Medicare payments for EsoGuard in October, a record month for test volume.
  • Cash was US$8.9 million at September 30, including US$5.3 million of restricted cash.

PAVM reported preliminary third-quarter 2026 results on November 13, 2026, for the quarter ended September 30. Revenue was US$41 thousand, against US$5 thousand a year earlier. Operating expenses were approximately US$6.8 million, including US$1.0 million of stock-based compensation. Research and Development expense was US$1,922 thousand, versus US$1,088 thousand a year earlier. Management said higher research and development expense relates largely to the Veris implantable device.

The net loss before noncontrolling interest and preferred dividends was approximately US$13 million, versus US$6 million a year earlier. Net loss attributable to PAVM common stockholders was US$11.8 million, which management said remains subject to the final Debt valuation analysis. The non-GAAP adjusted loss was US$1.2 million, or US$0.19 per share, versus US$446 thousand, or US$0.62 per share, a year earlier, and US$1.7 million in the second quarter. Management said the 10-Q is expected to be filed with the SEC on Monday.

Fair-Value Changes and the Lucid Stake

PAVM held 31.3 million shares of Lucid Diagnostics (NASDAQ:LUCD) at September 30, about 15% of LUCD's common stock and approximately 25% of voting interest together with its board and management. PAVM no longer has voting control of LUCD. The Equity method Investment balance was US$23.5 million, reflecting LUCD's closing price of US$0.75 on September 30 against US$1.07 at June 30.

Management described the decline of approximately US$10 million as a non-cash mark-to-market adjustment and the largest item in the quarter's profit and loss statement. The net charge from fair-value changes on the LUCD shares and the senior note was approximately US$9.6 million, against US$4.5 million in the prior-year quarter. The senior note was carried at US$14.2 million versus US$15.1 million at June 30, a US$300 thousand non-cash gain, and the US$15 million principal is unchanged. Non-GAAP operating expenses were US$5.6 million, about US$480 thousand below the second quarter and compared with a US$5.7 million average over the previous four quarters, according to management.

Medicare Payments, Pipeline Updates and Funding Position

LUCD began submitting EsoGuard claims through its Texas laboratory in late September and has been paid at the established Clinical Laboratory Fee Schedule rate since October, according to the company. LUCD performed 2,871 EsoGuard tests and recognized US$1.2 million of revenue in the quarter, and more than 1,800 tests in October. Management said Veris monthly enrollment at OSU-The James nearly doubled from July to September, and the company expects an FDA 510(k) submission for its implantable monitor in early 2027.

Cash was US$8.9 million at September 30, including US$5.3 million of restricted cash. Underlying burn was approximately US$2.8 million, versus US$2.7 million in the second quarter. The US$15 million senior secured note carries a 15% Interest Rate and matures in February 2029. PAVM did not satisfy the Collateral coverage covenant at September 30, and the noteholder agreed to waive it through the date of the SEC filing.

Quarter in Review: Results, Medicare Payments and Regulatory Dates

PAVM's third-quarter report combined preliminary financial results with updates across its portfolio. Net loss was approximately US$13 million, with a non-cash fair-value charge linked to its LUCD shares, and the non-GAAP adjusted loss was US$1.2 million. LUCD reported Medicare payments for EsoGuard beginning in October. Veris reported design freeze for its implantable monitor, a 90-day animal study started in October, and an FDA 510(k) submission planned for early 2027. PortIO has an FDA pre-submission meeting scheduled for January 2027, and Octeris expects enrollment in its University of North Carolina study in January 2027.